Positions

Overview

  • Steven M. Rowe was born in Baton Rouge, LA in May 1972. He received his BA degree from the University of Virginia in 1994, his medical degree from Vanderbilt University in 1998, and an MSPH from the University of Alabama at Birmingham in 2005. He completed a combined Internal Medicine and Pediatrics internship and residency at the University of Alabama at Birmingham. He also completed a combined Pulmonary and Critical Care Medicine and Pediatric Pulmonary fellowship at the University of Alabama at Birmingham.
    In 2014, Dr. Rowe was promoted to Professor with tenure in the Departments of Medicine (Pulmonary, Allergy, and Critical Care Medicine), Pediatrics (Pediatric Pulmonology), and Cell Developmental and Integrative Biology. He is the Director of the Gregory Fleming Cystic Fibrosis Research Center, which involves over 100 faculty members and has been continuously funded for over 25 years. Dr. Rowe is board certified in Internal Medicine, Pediatrics, Pulmonary Medicine and Critical Care Medicine and serves as a Special Consultant for Translational Science for the Cystic Fibrosis Foundation.
    Dr. Rowe has a remarkable ability to identify, establish, and cultivate effective collaborations across institutional and geographic boundaries. He established a prolific six-year collaboration with Dr. Guillermo Tearney to advance µOCT imaging for use in respiratory epithelia to ask seminal questions in airway biology. Dr. Rowe initiated an eight-year collaboration with Dr. Mark Dransfield to investigate acquired CFTR dysfunction in COPD. He has a seven-year collaboration with Dr. David Bedwell to advance translational readthrough approaches for genetic disease. Dr. Rowe is also highly effective in research consortia. He leads the International Mucus Clearance Consortium, involving Fundamental and translational scientists. He is also a key member of the cystic fibrosis research community, helping lead the Cystic Fibrosis Therapeutics Development Network through the Center for CFTR Detection.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.American Journal of Respiratory Cell and Molecular Biology.  64:604-616. 2021
    2021 A Phase 3 Open-Label Study of ELX/TEZ/IVA in Children 6 Through 11 Years of Age With CF and at Least One F508del Allele.American Journal of Respiratory and Critical Care Medicine2021
    2021 Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical TrialAnnals of the American Thoracic Society.  18:75-83. 2021
    2020 G551D mutation impairs PKA-dependent activation of CFTR channel that can be restored by novel GOF mutations 2020
    2020 Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTRAmerican Journal of Respiratory and Critical Care Medicine.  202:1271-1282. 2020
    2020 Novel therapy of bicarbonate, glutathione, and ascorbic acid improves cystic fibrosis mucus transportAmerican Journal of Respiratory Cell and Molecular Biology.  63:362-373. 2020
    2020 Airway remodeling in ferrets with cigarette smoke-induced COPD using μCT imaging 2020
    2020 Cystic fibrosis: Emergence of highly effective targeted therapeutics and potential clinical implicationsAmerican Journal of Respiratory and Critical Care Medicine.  201:1193-1208. 2020
    2020 Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutationAnnals of the American Thoracic Society.  17:212-220. 2020
    2020 Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with malesAmerican Journal of Respiratory and Critical Care Medicine.  201:996-998. 2020
    2019 Co-cultured microfluidic model of the airway optimized for microscopy and micro-optical coherence tomography imagingBiomedical Optics Express.  10:5414-5430. 2019
    2019 Vaporized e-cigarette liquids induce ion transport dysfunction in airway epitheliaAmerican Journal of Respiratory Cell and Molecular Biology.  61:162-173. 2019
    2019 The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: A case reportBMC Gastroenterology.  19. 2019
    2019 Acquired cystic fibrosis transmembrane conductance regulator dysfunction and radiographic bronchiectasis in current and former smokers: A cross-sectional studyAnnals of the American Thoracic Society.  16:150-153. 2019
    2018 Functional anatomic imaging of the airway surfaceAnnals of the American Thoracic Society.  15:S177-S183. 2018
    2018 Ataluren, a new therapeutic for alpha-1 antitrypsin-deficient individuals with nonsense mutationsAmerican Journal of Respiratory and Critical Care Medicine.  198:1099-1102. 2018
    2018 Maternal smoking induces acquired CFTR dysfunction in neonatal ratsAmerican Journal of Respiratory and Critical Care Medicine.  198:672-674. 2018
    2018 Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (GOAL): A clinical trialAmerican Journal of Respiratory and Critical Care Medicine.  198:526-528. 2018
    2018 Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvementAmerican Journal of Respiratory and Critical Care Medicine.  197:1483-1486. 2018
    2018 Seeing cilia: Imaging modalities for ciliary motion and clinical connections 2018
    2018 MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway EpitheliaAmerican Journal of Respiratory and Critical Care Medicine.  197:632-643. 2018
    2018 Not simply the lesser of two evils 2018
    2017 Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTRAnnals of the American Thoracic Society.  14:213-219. 2017
    2017 The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smokeAmerican Journal of Respiratory Cell and Molecular Biology.  56:99-108. 2017
    2016 Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutationsAmerican Journal of Respiratory and Critical Care Medicine.  194:1092-1103. 2016
    2016 Particle-Tracking Microrheology Using Micro-Optical Coherence TomographyBiophysical Journal.  111:1053-1063. 2016
    2016 In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomographyBiomedical Optics Express.  7:2494-2505. 2016
    2016 Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy 2016
    2016 Therapeutic approaches to acquired cystic fibrosis transmembrane conductance regulator dysfunction in Chronic bronchitisAnnals of the American Thoracic Society.  13:S169-S176. 2016
    2015 Recovery of acquired cystic fibrosis transmembrane conductance regulator dysfunction after smoking cessationAmerican Journal of Respiratory and Critical Care Medicine.  192:1521-1524. 2015
    2015 Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungsAmerican Journal of Respiratory Cell and Molecular Biology.  52:683-694. 2015
    2015 Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice 2015
    2014 A functional anatomic defect of the cystic fibrosis airwayAmerican Journal of Respiratory and Critical Care Medicine.  190:421-432. 2014
    2014 An autoregulatory mechanism governing mucociliary transport is sensitive to mucus loadAmerican Journal of Respiratory Cell and Molecular Biology.  51:485-493. 2014
    2014 Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosisAmerican Journal of Respiratory and Critical Care Medicine.  190:175-184. 2014
    2014 Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitisAmerican Journal of Respiratory Cell and Molecular Biology.  50:549-558. 2014
    2014 Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftorAmerican Journal of Respiratory Cell and Molecular Biology.  50:805-816. 2014
    2013 Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator functionAmerican Journal of Respiratory and Critical Care Medicine.  188:1321-1330. 2013
    2013 Cigarette smoke and CFTR: Implications in the pathogenesis of COPD 2013
    2013 Cystic fibrosis chronic rhinosinusitis: A comprehensive review 2013
    2012 Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulatorBiochemical Journal.  441:633-643. 2012
    2012 Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis 2012
    2011 Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators 2011
    2011 Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: Therapeutic implications for chronic rhinosinusitis 2011
    2010 Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: Potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescueAmerican Journal of Respiratory Cell and Molecular Biology.  43:607-616. 2010
    2009 Pharmaceuticals targeting nonsense mutations in genetic diseases: Progress in development 2009
    2008 Potential role of high-mobility group box 1 in cystic fibrosis airway diseaseAmerican Journal of Respiratory and Critical Care Medicine.  178:822-831. 2008
    2007 Restoration of W1282X CFTR activity by enhanced expressionAmerican Journal of Respiratory Cell and Molecular Biology.  37:347-356. 2007
    2007 Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trialsAnnals of the American Thoracic Society.  4:387-398. 2007
    2007 No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutationsAmerican Journal of Respiratory Cell and Molecular Biology.  37:57-66. 2007

    Research Overview

  • Dr. Rowe specializes in developing new treatments for cystic fibrosis, the most common autosomal recessive genetic disease, and the cause of severe pulmonary disease affecting children and young adults. He founded the CF Transition Clinic for adolescents and young adults with the disease. He maintains expertise in the design and conduct of clinical trials targeting the basic CF defect. Dr. Rowe also has an interest in biomarkers of CF and other related airway diseases including measures of ion transport and the relation between mucus stasis and inflammation. He currently directs a clinical research program that examines the relationship between CF and the chronic bronchitis of COPD.

    Dr. Rowe is an accomplished academic physician scientist- a pioneer in the field of personalized therapeutics for CF, cutting-edge discovery in airway disease biology, and translational research. He is a respected authority in the design and conduct of clinical trials targeting the basic CF defect and has made key advances in the measurement and interpretation of CFTR function in humans and animals. In a related effort, Dr. Rowe has advanced both the molecular and clinical understanding of suppression of premature termination codons, representing an exciting strategy for treatment of genetic diseases caused by nonsense mutations, which are responsible for approximately 10 percent of all genetic diseases.
    Dr. Rowe has recently discovered that COPD patients exhibit acquired CFTR dysfunction through a pathway that causes delayed mucociliary clearance and confers chronic bronchitis. The approach establishes how a single gene in a rare disorder can contribute to the third leading cause of death and has lead to new efforts to evaluate CFTR modulators in patients with chronic bronchitis, potentially leading to a new paradigm for COPD treatment. Dr. Rowe co-invented one-micron resolution optical coherence tomography that captures 3D imaging in real time at the cellular level. The technique is highly sensitive to the epithelial function of airway tissues and can provide simultaneous and non-invasive measurements of the functional microanatomy of the airway surface, significantly advancing our understanding of airway disease pathogenesis.
  • Principal Investigator On

  • Therapeutic Targeting of MUC5B in a Novel Ferret Model of Idiopathic Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2020 - 2024
  • Translational Program in CFTR-Related Airway Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2023
  • UAB Research and Development Program  awarded by Cystic Fibrosis Foundation ^ 2019 - 2023
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study) (PROMISE-OB-18)  awarded by Cystic Fibrosis Foundation ^ 2018 - 2023
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Admin Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Engineered PF Phage to treat pseudomonas aeruginosa biofilm infections  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - P&F Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2018 - 2022
  • Characterizing CFTR Modulated Changes in Sweat Chloride & Clinical Outcomes  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2017 - 2022
  • G551D Observational Study-Expanded to Additional Genotypes and Extended for Long Term Follow-Up (GOAL-e2)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2013 - 2022
  • Cystic Fibrosis Fibrosing Colonopathy Observational (CFFC-OB-11)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2012 - 2022
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2021 - 2022
  • Private Grant  awarded by ELOXX PHARMACEUTICALS 2020 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Consultant for Translational Science  awarded by Cystic Fibrosis Foundation ^ 2014 - 2021
  • Idiopathic Pulmonary Fibrosis, A Disease Initiated by Mucociliary Dysfunction  awarded by UNIVERSITY OF COLORADO DENVER - NEW 2017 - 2021
  • Private Grant  awarded by ELEVEN P15 INC 2019 - 2021
  • Core Center for Measurements of Mucus and Mucociliary Clearance  awarded by Cystic Fibrosis Foundation ^ 2020 - 2021
  • Characterizing CFTR Modulated Changes in Sweat Chloride and Clinical Outcomes  awarded by UNIVERSITY OF COLORADO DENVER - NEW 2017 - 2021
  • The Identification of New Treatments for Cystic Fibrosis Caused by Premature Termination Codons  awarded by SOUTHERN RESEARCH INSTITUTE 2015 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2016 - 2021
  • Mucociliary Clearance National Resource Center  awarded by University of North Carolina at Chapel Hill 2020 - 2021
  • UAB Cystic Fibrosis Translational Development Center  awarded by Cystic Fibrosis Foundation ^ 2017 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2019 - 2021
  • Mucus Matters: Mucociliary Physiology in Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2021
  • G551D Observational Study (GOAL-OB-11)  awarded by Cystic Fibrosis Foundation ^ 2011 - 2020
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2020
  • Mechanism of Aberrant Mucus Adhesion and Stasis in the CF Airways  awarded by Cystic Fibrosis Foundation ^ 2020
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2018 - 2020
  • Core Center for Measurements of Mucus and Mucociliary Clearance  awarded by Cystic Fibrosis Foundation ^ 2016 - 2020
  • Development of Optical Coherence Tomography for Measures of Mucociliary Clearance  awarded by MASSACHUSETTS GENERAL HOSPITAL 2016 - 2020
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) ("Clinical Study")  awarded by SEATTLE CHILDREN'S HOSPITAL 2014 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by ASTRAZENECA AB 2016 - 2019
  • TDN Additional Research Coordinator (ARC)  awarded by Cystic Fibrosis Foundation ^ 2014 - 2019
  • Private Grant  awarded by GALAPAGOS NV. 2016 - 2019
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2017 - 2019
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2018 - 2019
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2019
  • Research Development Program  awarded by Cystic Fibrosis Foundation ^ 2015 - 2019
  • Training and Equipment for the MBW sub-study of the PROSPECT Study.  awarded by Cystic Fibrosis Foundation ^ 2014 - 2019
  • A Pilot Study of the Effect of the CFTR Potentiator Ivacaftor in COPD (P-Topic)  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2019
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2019
  • Private Grant  awarded by ELOXX PHARMACEUTICALS 2017 - 2019
  • Private Grant  awarded by ASTRAZENECA AB 2015 - 2018
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)  awarded by Cystic Fibrosis Foundation ^ 2014 - 2018
  • Private Grant  awarded by GALAPAGOS NV. 2015 - 2018
  • The Mechanism of Tobacco-Induced Decrements in Mucociliary Clearance  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Mechanisms of and Therapies for Abnormal Mucus Adhesion and Clearance in CF  awarded by Cystic Fibrosis Foundation ^ 2016 - 2018
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2017 - 2018
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • UAB CF Research and Translation Core Center - Admin Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • UAB CF Research and Translation Core Center - Core C: Clinical & Translational Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • UAB CF Research and Translation Core Center - Pilot and Feasibility  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • Evaluation of Arina-1 for the Treatment of Cystic Fibrosis Lung Disease  awarded by CYSTIC FIBROSIS FOUNDATION THERAPEUTICS., INC 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by CFD RESEARCH CORPORATION 2016 - 2017
  • An Open Label N of 1 Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Ivacaftor in Combination with ALTALUREN (PTCD124) In Subjects with Nonsense Mutation Cystic Fibrosis  awarded by University of Pennsylvania 2016 - 2017
  • Private Grant  awarded by SYNEDGEN, INC 2016 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2015 - 2017
  • Private Grant  awarded by Bayer HealthCare 2014 - 2017
  • CFTR Functional Restoration by Antisense Oligonucleotides  awarded by Cystic Fibrosis Foundation ^ 2015 - 2017
  • Micro-CT Scanner for Ultra-High Resolution Live Imaging of Large and Small Animals  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2015 - 2017
  • Private Grant  awarded by PULMOTECT 2016 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2014 - 2017
  • Private Grant  awarded by GALAPAGOS NV. 2014 - 2017
  • Private Grant  awarded by PROGENRA, INC. 2016 - 2017
  • Brevenal Effect on Mucociliary Clearance for Treatment of CF Mucus  awarded by Cystic Fibrosis Foundation ^ 2016 - 2017
  • Effect of PAAG Treatment on CF Related Pseudomonas Infected Respiratory Epithelium  awarded by Cystic Fibrosis Foundation ^ 2016 - 2017
  • Functional Anatomic Imaging of CF Patients with Early Lung Disease Using microOCT  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2012 - 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2014 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2016 - 2017
  • Private Grant  awarded by Bayer AG 2014 - 2017
  • Evaluation of Approved Drug Libraries for Translational Readthrough Activity  awarded by Cystic Fibrosis Foundation ^ 2013 - 2017
  • Private Grant  awarded by SYNEDGEN, INC 2015 - 2017
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2016 - 2017
  • Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation ^ 2015 - 2016
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2014 - 2016
  • Private Grant  awarded by PROQR THERAPEUTICS 2015 - 2016
  • Private Grant  awarded by ORPRO THERAPEUTICS 2015 - 2016
  • Private Grant  awarded by RAPTOR PHARMACEUTICALS, INC. 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • Mechanistic Link Between Rescue of CFTR Mediated Anion Transport, Airway Surface Liquid Regulation, and Mucociliary Transport by CFTR Modulators  awarded by Cystic Fibrosis Foundation ^ 2010 - 2016
  • Private Grant  awarded by ELOXX PHARMACEUTICALS 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2016
  • Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2011 - 2016
  • The Mucociliary Clearance Defect of the Cystic Fibrosis Rat  awarded by Cystic Fibrosis Foundation ^ 2014 - 2016
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2013 - 2016
  • Private Grant  awarded by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2014 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by Bayer AG 2014 - 2016
  • Therapeutic Development Center - UAB Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^ 2013 - 2015
  • Development of Optical Coherence Tomography for Measures of Mucociliary Clearance (MCC)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2008 - 2015
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2015
  • The 2015 TDN Spring Meeting  awarded by Cystic Fibrosis Foundation ^ 2015
  • Nasal Epithelial Cells as an Outcome Tool for Individualized CFTR Therapies  awarded by Cystic Fibrosis Foundation ^ 2014 - 2015
  • Private Grant  awarded by SYNEDGEN, INC 2013 - 2015
  • Restoration of the CFTR Function by Splicing Modulation  awarded by Cystic Fibrosis Foundation ^ 2013 - 2015
  • Assessing Response of B-Adrenergic Sweat Secretion in Patients with R117H Mutations Following Treatment with Ivacaftor (GOALe2 Ancillary)  awarded by Cystic Fibrosis Foundation ^ 2014 - 2015
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2013 - 2015
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^ 2013 - 2014
  • Consultant for Translational Science  awarded by Cystic Fibrosis Foundation ^ 2009 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2010 - 2014
  • G551D Observational Study-SEATTLE GOAL  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2012 - 2014
  • Private Grant  awarded by SYNEDGEN, INC 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Systemic CFTR Dysfunction Induced by Acrolein in Cigarette Smoke: A Novel Therapeutic Target for COPD  awarded by American Lung Association 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by DISCOVERY BIOMED, LLC ^ 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Individual Project Schedule #6.0  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2011 - 2013
  • Characterization of Novel Translational Readthrough Agents Discovered by High Throughput Screening  awarded by Cystic Fibrosis Foundation ^ 2012 - 2013
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2010 - 2013
  • Genetic Modifiers of Cystic Fibrosis  awarded by Johns Hopkins University 2011 - 2013
  • Development of High Through-Put Screening by SD-OCT in Primary Human Bronchial Epithelial Cells  awarded by FLATLEY DISCOVERY LAB, LLC 2011 - 2013
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2009 - 2013
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2011 - 2012
  • UAB Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^ 2011 - 2012
  • UAB Cystic Fibrosis Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^ 2011 - 2012
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2011 - 2012
  • Mechanistic Basis Underlying Protein Repair of CFTR Nonsense Mutations  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2009 - 2012
  • UAB CF Research and Translation Core Center - Core C - Clinical Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2007 - 2012
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2009 - 2012
  • Private Grant  awarded by HEMAQUEST PHARMACEUTICALS, INC. 2011 - 2012
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2009 - 2011
  • CFF Clinical Fellowship  awarded by Cystic Fibrosis Foundation ^ 2009 - 2011
  • Clinical and Mechanistic Features of Premature Termination Codon Suppression  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2006 - 2011
  • Using Chamber Studies to Characterize CFTR Modulators  awarded by Cystic Fibrosis Foundation ^ 2009 - 2011
  • UAB CF Research and Translation Core Center - Pilot Project 1 - Mucoid Steptococcus Pseumoniae in the CF Lung  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2007 - 2009
  • Investigator On

  • Pharmacometric Approaches to Precision Optimization of Ivacaftor Response in Cystic Fibrosis Patients  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2020 - 2025
  • Center for Clinical and Translational Science (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - A Multicenter Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Multicenter Topic Trial).  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2022
  • A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2020 - 2022
  • Dysbiosis of the Sinus Microbiota in Chronic Rhinosinusitis  awarded by Cystic Fibrosis Foundation ^ 2020 - 2022
  • Dysbiosis of the Sinus Microbiota in Chronic Rhinosinusitis  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2019 - 2022
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2021 - 2022
  • Private Grant  awarded by ELECTROMED, INC. 2020 - 2021
  • miR-145 Target Site Blockade to Amplify CFTR Correction  awarded by Cystic Fibrosis Foundation ^ 2019 - 2021
  • Overcoming Barriers to F508del CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2021
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2021
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2021
  • Exacerbation of Influenza Secondary Infections in Cystic Fibrosis  awarded by Cystic Fibrosis Foundation ^ 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Oligotherapeutics to Enhance CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2021
  • Rare CFTR Mutation Cell Collection Protocol (RARE)  awarded by SEATTLE CHILDREN'S HOSPITAL 2016 - 2021
  • Mechanisms of and Therapies for Abnormal Mucus Adhesion and Clearance in CF  awarded by Cystic Fibrosis Foundation ^ 2020 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL 2018 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2021
  • Novel Therapeutic Approaches for Treatment of CF Patients with W1282X Premature Termination Codon Mutations  awarded by EMILY'S ENTOURAGE 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2021
  • UAB Cystic Fibrosis Therapeutic Development Network Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^ 2016 - 2021
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2018 - 2020
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2018 - 2020
  • Standardized Treatment of Pulmonary Exacerbations II  awarded by SEATTLE CHILDREN'S HOSPITAL 2016 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Losartan as Anti-Inflammatory Therapy to Augment F508del CFTR Recovery  awarded by University of Miami 2017 - 2019
  • MiR-145 Mediated TGF-Beta Pathobiology in CF  awarded by Cystic Fibrosis Foundation ^ 2017 - 2019
  • Private Grant  awarded by PARION SCIENCES, INC. 2016 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • Private Grant  awarded by ASTRAZENECA AB 2017 - 2018
  • Private Grant  awarded by CELTAXSYS, INC. 2016 - 2018
  • Sweat Gland Culture Techniques for the Study of Cystic Fibrosis  awarded by Cystic Fibrosis Foundation ^ 2015 - 2018
  • Proof of Principal Evaluation of IV Gallium Nitrate (Ganite) in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL 2013 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research (Adult)  awarded by Cystic Fibrosis Foundation ^ 2011 - 2017
  • Private Grant  awarded by Gilead Sciences ^ 2017
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2016 - 2017
  • Private Grant  awarded by PROQR THERAPEUTICS 2015 - 2016
  • Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2013 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • CFF Yr 3-Reproductive and Sexual Health Care in Young Women with CFF  awarded by University of Pittsburgh The 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2012 - 2016
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2015
  • UAB Center for Clinical and Translational Science (CCTS) (3 linked awards: UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2014 - 2015
  • UAB Research Development Program Component II - Overall Program  awarded by Cystic Fibrosis Foundation ^ 2015
  • Tuning Aminoglycosides for Treatment of Genetic Diseases  awarded by Technion Israel Institute of Technology 2011 - 2015
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2015
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2014 - 2015
  • Private Grant  awarded by FOREST LABORATORIES, INC. 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • UAB Center for Clinical and Translational Science (CCTS) UL1  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2011 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2013
  • Pediatric Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^ 2004 - 2013
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2007 - 2012
  • Education And Training

  • Master of Science in Biostatistics, University of Alabama at Birmingham 2005
  • Doctor of Medicine, Vanderbilt University 1998
  • UAB Hospital, Internship 1999
  • UAB Hospital, Residency 2002
  • UAB Hospital, Postdoctoral Fellowship 2005
  • Full Name

  • Steven Rowe